Caribou Biosciences, a clinical-stage biopharmaceutical company specializing in CRISPR genome editing, has announced the appointment of Sri Ryali as its Chief Financial Officer. With two decades of finance and commercial expertise in the biopharmaceutical sector, Ryali will oversee corporate finance, investor relations, and corporate communications, reporting directly to CEO Rachel Haurwitz. His leadership is poised to be instrumental as Caribou progresses its clinical-stage programs targeting hematologic malignancies and autoimmune diseases, alongside ambitious plans to release multiple datasets in 2025. Haurwitz highlighted Ryali’s extensive experience in drug development and commercialization as a critical asset to the company’s future growth.
Ryali previously served as CFO at Codexis and Eiger BioPharmaceuticals, where he played pivotal roles in financial and operational strategies during key growth stages. His career also includes significant tenures at Aimmune Therapeutics, Onyx Pharmaceuticals, and Amgen, where he spearheaded finance initiatives. Excited to join Caribou, Ryali praised the company’s momentum in developing off-the-shelf CAR-T cell therapies to address unmet patient needs. With his financial expertise and business acumen, Ryali aims to bolster Caribou’s mission to deliver accessible and effective treatments for patients with severe diseases.
